Oramed Pharmaceuticals Inc (ORMP)

10.71
1.21 12.74
NASDAQ : Health Care
Prev Close 9.50
Open 9.55
Day Low/High 9.55 / 10.87
52 Wk Low/High 4.15 / 10.74
Volume 148.25K
Avg Volume 55.70K
Exchange NASDAQ
Shares Outstanding 13.32M
Market Cap 126.82M
EPS -0.90
P/E Ratio 10.94
Div & Yield N.A. (N.A)

Latest News

Oramed Announces Successful Meeting With FDA For Oral Insulin

Oramed To Present At The Rodman & Renshaw Global Investment Conference
Oramed Appoints Dr. Simon Bruce As Vice President Of Medical Affairs

Oramed Appoints Dr. Simon Bruce As Vice President Of Medical Affairs

Oramed To Present At BIT'S 5th World Congress Of Diabetes On July 13, 2017

Oramed To Present At BIT'S 5th World Congress Of Diabetes On July 13, 2017

Oramed Announces End-of-Phase 2 Meeting With FDA To Initiate Phase 3 Program

Oramed Announces End-of-Phase 2 Meeting With FDA To Initiate Phase 3 Program

Oramed Announces Dual-Listing On Tel Aviv Stock Exchange

Oramed Announces Dual-Listing On Tel Aviv Stock Exchange

Oramed Granted Japanese Patent For Combination Insulin And GLP-1 Analog Capsule

Oramed To Present At The American Diabetes Association 77th Scientific Sessions

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

Oramed Granted Canadian Patent For GLP-1 Analog Capsule

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Oramed Receives Israel Regulatory Approval To Conduct Human Study For New Oral Leptin Capsule

Oramed Granted European Patent For Combination Oral Insulin And GLP-1 Analog Capsule

Journal Of Diabetes Science And Technology Publishes Scientific Paper Authored By Oramed Scientists

Oramed Appoints Dr. Ronald Law As Chief Strategy Officer

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

These under-$10 stocks are within range of triggering big breakout trades.

A Speculative Biotech Catalyst Trade: ORMP

A Speculative Biotech Catalyst Trade: ORMP

This beaten-down biotech stock could be ripe for a rebound.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:

[video] Quick Take: Revolutionizing Diabetes Treatment

[video] Quick Take: Revolutionizing Diabetes Treatment

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Seeking to Remake Diabetes Therapy

Seeking to Remake Diabetes Therapy

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Marking a major milestone for the company, Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( http://www.

Oramed Pharmaceuticals Chosen To Present At The XVI International Symposium On Atherosclerosis (ISA2012), (March 25-29, 2012; Sydney, Australia)

Oramed Pharmaceuticals Chosen To Present At The XVI International Symposium On Atherosclerosis (ISA2012), (March 25-29, 2012; Sydney, Australia)

Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( www.

Load More
Quant Rating on 4:00 PM EDT 9/22/2017

D-

(Sell)

From Our Partners

Premarket Gainers as of 9:05 am
SeekingAlpha

Oramed announces successful meeting with FDA for oral insulin; shares ahead 15% premarket
SeekingAlpha

Oramed: On To Phase III And The Tel Aviv Stock Exchange
SeekingAlpha

Daily Insider Ratings Round Up 8/3/17: PLSE, IPI, IFF, NUVA
SeekingAlpha

Oramed Pharma to list shares on Tel-Aviv Stock Exchange; shares ahead 3%
SeekingAlpha

InsiderInsights.com Daily Round Up 4/19/17: Apollo Global, Pulse Biosciences, Acacia Communications, JPMorgan China Region Fund, Clough Global Opportunities Fund
SeekingAlpha

Here's Where Oramed Fits Into The Diabetes Space
SeekingAlpha

Oramed Vs. Novo Nordisk In Race For Oral GLP-1
SeekingAlpha

Diabetes Patients Need Earlier Administration Insulin: Novo Nordisk And Oramed Take The Lead
SeekingAlpha

Novo Nordisk Vs. Oramed - A Second Look At The Battle For Oral Insulin
SeekingAlpha

The Battle For Oral Insulin
SeekingAlpha

Oramed initiated with an Outperform at FBR Capital
The Fly

Oramed initiated with a Buy at Rodman & Renshaw
The Fly

Oramed Pharmaceuticals (ORMP) in Focus: Stock Up 19.2% - Tale of the Tape
Zacks

Oramed Receives EU Patent for Oral Delivery of Insulin
Benzinga
TheStreet Quant Rating: D- (Sell)

Get the (ORMP)
Report Here

Watchlist

Trending
Here Comes the Meltdown as Goldman Sachs Sees 9 Interest Rate Hikes by 2019
It Would Be 'Crazy' to Clean House at Wells Fargo, CEO Says
The 12 Absolutely Cheapest Places to Buy a House in America